Life Expectancy and Causes of Death in Patients with Myotonic Dystrophy Type 2
Journal of Neuromuscular Diseases · 2024
DOI: 10.3233/jnd-240089 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Neuromuscular Diseases, 2024. Verfasst von Manon J Damen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Life Expectancy, Myotonic Dystrophy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myotonic Dystrophy type 2 (DM2) is a dominantly inherited multisystem disease caused by a CCTG repeat expansion in intron 1 of the CNBP gene. Although in the last two decades over 1500 patients with DM2 have been diagnosed worldwide, our clinical impression of a reduced life expectancy in DM2 has not been investigated previously.
Objective
The aim of this observational study was to determine the life expectancy and the causes of death in patients with genetically confirmed DM2.
Methods
We identified the data of all deceased patients with DM2 in the Dutch neuromuscular database between 2000 and 2023. Ages and causes of death and the patients’ clinical features during lifetime were determined. Age of death in DM2 was compared to the general population by using life tables with prognostic cohort life expectancy (CLE) and period life expectancy (PLE) data of the Dutch electronic database of statistics (CBS StatLine).
Results
Twenty-six deceased patients were identified in the Dutch DM2 cohort (n = 125). Median age of death in DM2 (70.9 years) was significantly lower compared to sex- and age-matched CLE (78.1 years) and PLE (82.1 years) in the Netherlands. Main causes of death were cardiac diseases (31%) and pneumonia (27%). Seven patients (27%) had a malignancy at the time of death.
Conclusion
These results provide new insights into the phenotype of DM2. Life expectancy in patients with DM2 is reduced, possibly attributable to multiple causes including increased risk of cardiac disease, pneumonia, and malignancies. The occurrence of a significantly reduced life expectancy has implications for clinical practice and may form a basis for advanced care planning, including end-of-life care, to optimize quality of life for patients with DM2 and their family. Research in larger cohorts should be done to confirm these findings and to ascertain more about the natural course in DM2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Neurology, Medisch Spectrum Twente, Enschede, The Netherlands.
- Department of Neurology, Rijnstate Hospital, Arnhem, The Netherlands.
Zitieren
APA
Damen, M. J., Muilwijk, O. G., Olde Dubbelink, T. B., van Engelen, B. G., Voermans, N. C., & Tieleman, A. A. (2024). Life Expectancy and Causes of Death in Patients with Myotonic Dystrophy Type 2. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-240089
Vancouver
Damen MJ, Muilwijk OG, Olde Dubbelink TB, van Engelen BG, Voermans NC, Tieleman AA. Life Expectancy and Causes of Death in Patients with Myotonic Dystrophy Type 2. Journal of Neuromuscular Diseases. 2024. doi:10.3233/jnd-240089
BibTeX
@article{Damen2024,
author = {Damen, Manon J and Muilwijk, Otto G and Olde Dubbelink, Tom Bg and van Engelen, Baziel Gm and Voermans, Nicol C and Tieleman, Alide A},
title = {Life Expectancy and Causes of Death in Patients with Myotonic Dystrophy Type 2},
journal = {Journal of Neuromuscular Diseases},
year = {2024},
doi = {10.3233/jnd-240089}
}
EUVIMED